Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blink Tears is an over-the-counter (OTC) lubricating ophthalmic solution used for the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. The formulation primarily contains polyethylene glycol 400 (0.4%) as a lubricant and humectant, which works by stabilizing the tear film and reducing ocular surface friction. It also incorporates sodium hyaluronate, a viscoelastic polymer that mimics the natural mucin layer of the eye to enhance moisture retention and provide prolonged comfort. Originally developed by Abbott Medical Optics (AMO), the brand was later acquired by Johnson & Johnson Vision Care and subsequently by Bausch + Lomb in 2023. It is frequently utilized to manage symptoms of mild to moderate dry eye disease and to improve ocular comfort following ophthalmic procedures such as cataract surgery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on blink tears.